Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology–KROG/RTOG 1119 Phase 2 Randomized Trial
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2023.07.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von In Ah Kim und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Seoul National University, Seoul, South Korea. Electronic address: inah228@snu.ac.kr. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Radiosurgery. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE: Lapatinib plus whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) was hypothesized to improve the 12-week intracranial complete response (CR) rate compared with either option of radiation therapy (RT) alone for patients with brain metastases (BM) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer. METHODS AND MATERIALS: This study included patients with HER2+ breast cancer with ≥1 measurable, unirradiated BM. Patients were randomized to WBRT (37.5 Gy/3 wk)/SRS (size-based dosing) ± concurrent lapatinib (1000 mg daily for 6 weeks). Secondary endpoints included objective response rate (ORR), lesion-specific response, central nervous system progression-free survival, and overall survival. RESULTS: From July 2012 to September 2019, 143 patients were randomized, with 116 analyzable for the primary endpoint. RT + lapatinib did not improve 12-week CR (0% vs 6% for RT alone, 1-sided P = .97), or ORR at 12 weeks. At 4 weeks, RT + lapatinib showed higher ORR (55% vs 42%). Higher graded prognostic assessment and ≤10 lesions were associated with higher 12-week ORR. Grade 3 and 4 adverse event rates were 8% and 0% for RT and 28% and 6% for RT + lapatinib. CONCLUSIONS: The addition of 6 weeks of concomitant lapatinib to WBRT/SRS did not improve the primary endpoint of 12-week CR rate or 12-week ORR. Adding lapatinib to WBRT/SRS showed improvement of 4-week ORR, suggesting a short-term benefit from concomitant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Seoul National University, Seoul, South Korea. Electronic address: inah228@snu.ac.kr.
- NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
- Radiation Oncologist, Minneapolis Radiation Oncology, Minneapolis, Minnesota.
- Department of Radiation Oncology, Grandview Medical Center, Birmingham, Alabama.
- Brain Tumor & Neuro-Oncology Cleveland Clinic Main Campus, Cleveland, Ohio.
- Medical Physics Department, Northside Hospital Cancer Institute, Atlanta, Georgia.
Förderung
- NCI NIH HHS
Zitieren
APA
Kim, I. A., Winter, K. A., Sperduto, P. W., De Los Santos, J. F., Peereboom, D. M., Ogunleye, T., Boulter, D., Fritz, J. M., Cho, K. H., Shin, K. H., Zoberi, I., Choi, S., Palmer, J. D., Liem, B., Kim, Y. B., Anderson, B. M., Thakrar, A. W., Muanza, T. M., Kim, M. M., …, & White, J. R. (2024). Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology–KROG/RTOG 1119 Phase 2 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.07.019
Vancouver
Kim IA, Winter KA, Sperduto PW, De Los Santos JF, Peereboom DM, Ogunleye T, et al. Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology–KROG/RTOG 1119 Phase 2 Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2023.07.019
BibTeX
@article{Kim2024,
author = {Kim, In Ah and Winter, Kathryn A and Sperduto, Paul W and De Los Santos, Jennifer F and Peereboom, David M and Ogunleye, Tomi and Boulter, Daniel and Fritz, Joel M and Cho, Kwan Ho and Shin, Kyung Hwan and Zoberi, Imran and Choi, Serah and Palmer, Joshua D and Liem, Ben and Kim, Yong Bae and Anderson, Bethany M and Thakrar, Anupama W and Muanza, Thierry M and Kim, Michelle M and Choi, Doo Ho and Mehta, Minesh P and White, Julia R},
title = {Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology–KROG/RTOG 1119 Phase 2 Randomized Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2023.07.019}
}
EUVIMED